Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of...
-
Upload
solomon-morgan -
Category
Documents
-
view
223 -
download
2
Transcript of Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of...
Breast conservation in Locally advanced breast cancer
Department of Endocrine Surgery
College of MedicineAmrita Institute of Medical Sciences
Kochi, Kerala.
S. Vaidyanathan
These Power Point presentations are free to download only for academic purposes, with due acknowledgements to authors and this website.
Neoadjuvant Chemotherapy (NACT)
• Heralded as future of breast cancer treatment. (NSABP18 and EORTC trials)
• FAC/Anthracycline related groupsPositive tumor responseDown staged tumorMastectomy / BCT No survival benefit
NACT- facts
Fact• Need for Mastectomy reduced• Clinical response important
predictor of response• p CR of primary and nodes
predicts outcome• Does not offer survival benefit• Does not increase risk of local
recurrence
Level of evidence• Level I• Level I
• Level I
• Level I• Level II
Sequence in LABC
• Neoadjuvant chemotherapy
• Locoregional surgery – Mastectomy / BCT
• Completion chemotherapy
• Locoregional RT (?)
• Tamoxifen if ER +ve
BCT in LABC - the evidence
• 120 patients LABC – non inflammatory
• 4 courses of induction CT
• Preoperative RT• 5th course of anthracycline
(Le Rouge, Touboul et al. J.Radiation Oncology, biology and physics;2004: 59:1069-53)
Evidence -contd
• Mastectomy + AD – Residual tumor > 3 cm, central, bifocal – 49
• BCS + AD+ boost to excision site - Residual tumor < 3cm – 39
• Radiation to tumor bed -Complete clinical response / Partial response over 90% - 32
Evidence outcome
Mastectomy Group
BCS group RT group
10 yr local recurrence
4% 23% 13%
Conclusion : BCS feasible in LABC but associated with high local recurrence
BCS in LABC High local recurrence
• Clinical response vs Pathologic complete response. 80% - 15%.(Fischer et al , J.of Oncology.1998:16; 267-85)
• Therapy induced tumor regression – patchy and not concentric
• Volume of tissue resected smaller than volume of original tumor. Davidson and Morrow, J. National cancer institute. 2005: 97;159-60
Pathological response
1. Complete response – (p CR) –no residual invasive cells in the breast and axillary contents
2. Partial response – (p PR) –less than 10 microscopic foci of invasive cells
3. No response –( p NR)- All other cases
BCS in LABCStrategies to Improve outcome
• Improve pathological response
- concurrent chemoradiation
- Taxanes – Single / Sequential
• Dannenburg and Formenti trialsImprovement of pathological
response
Predictors of therapeutic response
• Dynamic MRI
• Stereotactic localization of tumor margins
• Molecular markersto choose chemotherapy - p53 negative – 5FU/ RT
-HER -2 neu negative – Paclitaxel /RT
Current recommendations for Surgery in LABC
• Initial tumor size < 6 cm
• Post NACT tumor size < 3 cm• Without extensive nodal disease
(Le Rouge, Touboul et al. J.Radiation Oncology, biology and physics;2004: 59:1069-53)
LABC - surgical optionsRecommendations of Tata Memorial Hospital
• Complete response –Clinical/ mammogram Index Quadrantectomy+AD
• Partial response –Radiological residual disease# BCT + AD# Simple mastectomy + AD
• Static / Progressive disease # SM + AD # Reconstruction for skin cover # Post op radiation
• Inoperability RT – reassess for excision